https://doi.org/10.1016/j.vaccine.2006.11.011

">
 

Title

Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults

Publication Date

3-1-2007

Document Type

Article

Publication Title

Vaccine

Abstract

Objective: To evaluate immunogenicity and tolerability of a live attenuated zoster vaccine in varicella-zoster virus (VZV) seronegative or low-seropositive adults ≥30 years of age. Study design: Double-blind, placebo-controlled, randomized, multicenter study. Subjects were enrolled in two stages by prescreened serostatus. Subjects with a low VZV antibody titer (≤5 gpELISA units/mL) were enrolled in Stage 1. Subjects with undetecable VZV antibodies and no safety issues identified during Stage 1 were enrolled in Stage 2. All enrolled subjects were randomized 4:1 to receive one dose (∼50,000 PFU) of zoster vaccine or placebo and were followed for safety for 42 days postvaccination. Primary objectives/hypotheses: (1) no vaccine-related serious adverse experiences (AE); (2) ≤1 laboratory-confirmed varicella-like rash with >50 lesions within 42 days postvaccination. Secondary objective: summarize the VZV antibody response postvaccination. Results: Twenty-one subjects (age 27 to 69 years; median 34) enrolled (1148 prescreened); 18 (including 4 seronegative subjects) received vaccine and 3 (including 1 seronegative subject) received placebo. Twenty subjects completed the study; one subject withdrew for reasons unrelated to safety. No serious vaccine-related AE or laboratory-confirmed varicella-like rashes with >50 lesions were reported. In the zoster vaccine group, all 4 of the initially seronegative subjects (age 32 to 36 years; median 33.5) seroconverted and 6 of the 13 (46.2%) initially seropositive subjects had a ≥4-fold rise in VZV-specific antibody titer at 6 weeks postvaccination. Conclusions: The zoster vaccine appears to be immunogenic and generally well tolerated in healthy adults ≥30 years of age, regardless of initial VZV antibody serostatus. © 2006 Elsevier Ltd. All rights reserved.

First Page

2139

Last Page

2144

To view the document, please click the DOI link after the APA Citation.

Share

COinS